Screener
Regeneron Pharmaceuticals REGN EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Regeneron Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
FAQ
- What is Regeneron Pharmaceuticals's EV / EBITDA?
- Regeneron Pharmaceuticals (REGN) reported EV / EBITDA of 15× in Q2 2026.
- How has Regeneron Pharmaceuticals's EV / EBITDA changed year-over-year?
- Regeneron Pharmaceuticals's EV / EBITDA increased by 14.4% year-over-year, from 13.1× to 15×.
- What is the long-term trend for Regeneron Pharmaceuticals's EV / EBITDA?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's EV / EBITDA has grown at a 7.4% compound annual growth rate (CAGR), from 13.8× to 19.6×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Regeneron Pharmaceuticals's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude